✦ LIBER ✦
Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs
✍ Scribed by Curtis, J. R. ;Martin, C. ;Saag, K. G. ;Patkar, N. M. ;Kramer, J. ;Shatin, D. ;Allison, J. ;Braun, M. M.
- Book ID
- 101653719
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 62 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Dr. Saag has received consulting fees and/or honoraria (less than $10,000) and grant support from Amgen. Dr. Kramer has served as a consultant to the FDA in designing, analyzing, and interpreting a study on heart failure associated with tumor necrosis factor inhibitors and has received consulting fees ($10,000) from the FDA. Dr. Kramer has served as a consultant on the Engalitcheff grant awarded to the University of Alabama.